Caroline Borders
Vice President, Investor Relations
Replay available
GE HealthCare Technologies Inc. (NASDAQ: GEHC) Q1 2026 earnings conference call, held 2026-04-29. Replay captured from the company's public earnings webcast.

Vice President, Investor Relations
President and Chief Executive Officer
Vice President and Chief Financial Officer
Analyst, Evercore ISI
Analyst, Citi
Analyst, Bank of America Securities
Analyst, JPMorgan Chase
Analyst, Goldman Sachs
Analyst, Wells Fargo
Analyst, Jefferies
Analyst, BTIG
Analyst, Mizuho
Good day and thank you for standing by. Welcome to the GE Healthcare first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, please press star 11 again. please be advised that today's conference is being recorded. Now it's my pleasure to hand the conference over to Caroline Borders. Please proceed. Thanks, Operator. Good morning and welcome to GE Healthcare's first quarter 2026 earnings call. I'm joined by our President and CEO, Peter Arduini, and Vice President and CFO, Jay Saccaro. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. With that, I'll turn the call over to Peter. Thanks, Carolyn. Good morning, and thank you for joining us. Let me start with our performance in the first quarter of 2026. We were pleased with the top line growth that came in at the high end of our expectations, driven by our pharmaceutical diagnostics, advanced visualization solutions, and imaging businesses. We also had strong services growth in the quarter. This all reflects disciplined commercial execution and accelerated customer adoption of new products designed to help clinicians en...